14-3-3 protein is a component of Lewy bodies in Parkinson's disease - Mutation analysis and association studies of 14-3-3 eta

Molecular Brain Research

Volumn 108, Issue 1-2, 2002, Pages 33-39

  Ubl, Andreas ^a   Berg, Daniela ^b   Holzmann, Carsten ^a   Krüger, Rejko ^c   Berger, Klaus ^d   Arzberger, Thomas ^b   Bornemann, Antje ^c   Riess, Olaf ^a,c  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

14 3 3 eta; Association studies; Lewy body; Mutation analysis; Parkinson's disease

Indexed keywords

GENE PRODUCT; PROTEIN 14 3 3; PROTEIN ANTIBODY; TYROSINE 3 MONOOXYGENASE; YWHAH PROTEIN, HUMAN;

ARTICLE; CHROMOSOME 22Q; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEWY BODY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SUBSTANTIA NIGRA; AGED; ALLELE; CHEMISTRY; CHROMOSOME 22; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

14-3-3 PROTEINS; AGED; ALLELES; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 22; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODIES; MALE; MIDDLE AGED; PARKINSON DISEASE; TYROSINE 3-MONOOXYGENASE;

EID: 1842832448     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(02)00510-7     Document Type: Article

References (41)

1. Aitken A., Howell S., Jones D., Madrazo J., Patel Y. 14-3-3 α and δ are the phosphorylated forms of Raf-activating 14-3-3 β and ζ J. Biol. Chem. 270:1995;5706-5709.
2. Aitken A. 14-3-3 and its possible role in co-ordinating multiple signaling pathways. Trends Cell Biol. 6:1996;341-347.
3. Armstrong M., Daly A.K., Cholerton S., Bateman D.N., Idle J.R. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet. 339:1992;1017-1018.
4. Bell R., Munro J., Russ C., Powell J.F., Bruinvels A., Kerwin R.W., Collier D.A. Systematic screening of the 14-3-3 eta (η) chain gene for polymorphic variants and case-control analysis in schizophrenia. Am. J. Med. Genet. 96:2000;736-743.
5. Berger K., Hense H.W., Rothdach A., Weltermann B., Keil U. A single question about prior stroke versus a stroke questionnaire to assess stroke prevalence in populations. Neuroepidemiology. 19:2000;245-257.
6. Boston P.F., Jackson P., M Kynoch P.A., Thompson R.J. Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J. Neurochem. 38:1982;1466-1474.
7. Brandel J.-P., Peoc'h K., Beaudry P., Welaratne A., Bottos C., Agid Y., Laplanche J.-L. 14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeld-Jakob disease patients. Ann. Neurol. 49:2001;257-260.
8. Couve A., Kittler J.T., Uren J.M., Calver A.R., Pangalos M.N., Walsh F.S., Moss S.J. Association of gaba(b) receptors and members of the 14-3-3 family of signaling proteins. Mol. Cell. Neurosci. 17:2001;317-328.
9. Gelperin D., Weigle J., Nelson K., Roseboom P., Irie K., Matsumoto K., Lemmon S. 14-3-3 proteins: potential roles in vesicular transport and Ras signaling in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA. 92:1995;11539-11543.
10. Hayakawa T., Ishiguro H., Toru M., Hamaguchi H., Arinami T. Systematic search for mutations in the 14-3-3 η chain gene on chromosome 22 in schizophrenics. Psychiat. Genet. 8:1998;33-36.
11. Hsu S.M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29:1981;577-580.
12. Ichimura T., Isobe T., Okuyama T., Yamauchi T., Fujisawa H. Brain 14-3-3 protein is an activator protein that activates tryptophan 5′-monooxygenase and tyrosine 3′-monooxygenase in the presence of Ca2+, calmodulin-dependent protein kinase II. FEBS Lett. 219:1987;78-82.
13. Ichimura T., Sugano H., Kuwano R., Sunaya T., Okuyama T., Isobe T. Widespread distribution of the 14-3-3 protein in vertebrate brains and bovine tissues: correlation with the distribution of calcium-dependent protein kinase. J. Neurochem. 56:1991;1449-1451.
14. Ichimura-Ohshima Y., Morii K., Ichimura T., Araki K., Takahashi Y., Isobe T., Minoshima S., Fukuyama R., Shimizu N., Kuwano R. cDNA cloning and chromosome assignment of the gene for human brain 14-3-3 protein eta chain. J. Neurosci. Res. 31:1992;600-605.
15. Kawamoto Y., Akiguchi I., Nakamura S., Honjyo Y., Shibasaki H., Budka H. 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J. Neuropathol. Exp. Neurol. 61:2002;245-253.
16. Kimura M.T., Irie S., Shoji-Hoshino S., Mukai J., Nadano D., Oshimura M., Sato T.A. 14-3-3 is involved in p75 neurotrophin receptor (p75NTR)-mediated signal transduction. J. Biol. Chem. 276:2001;17291-17300.
17. Krüger R., Kuhn W., Müller Th., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18:1998;106-108.
18. Layfield R., Fergusson J., Aitken A., Lowe J., Landon M., Mayer R.J. Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci. Lett. 209:1996;57-60.
19. Louis E.J., Dempster E.R. An exact test of Hardy-Weinberg proportions for multiple alleles. Biometrics. 43:1987;800-802.
20. Martin H., Rostas J., Patel Y., Aitken A. Subcellular localisation of 14-3-3 isoforms in rat brain using specific antibodies. J. Neurochem. 63:1994;2259-2265.
21. Mils V., Baldin V., Goubin F., Pinta I., Papin C., Waye M., Eychene A., Ducommun B. Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase. Oncogene. 19:2000;1257-1265.
22. Muratake T., Hayashi S., Ichikawa T., Kumanishi T., Ichimura Y., Kuwano R., Isobe T., Wang Y., Minoshima S., Shimizu N., Takahashi Y. Structural organization and chromosomal assignment of the human 14-3-3 eta chain gene (YWHAH). Genomics. 36:1996;63-69.
23. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. α-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19:1999;5782-5791.
24. Raymond M., Rousset F. Genepop (version 1.2): population genetics software for exact tests and ecumenicism. J. Hered. 86:1995;248-249.
25. Krüger R., Eberhardt O., Riess O., Schulz J.B. Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol. Med. 8:2002;236-240.
26. Roth D., Birkenfeld J., Betz H. Dominant-negative alleles of 14-3-3 proteins cause defects in actin organization and vesicle targeting in the yeast Saccharomyces cerevisiae. FEBS Lett. 460:1999;411-416.
27. Rousset F., Raymond M. Testing heterozygote excess and deficiency. Genetics. 140:1995;1413-1419.
28. Saiz A., Graus F., Dalmau J., Pifarré A., Marin C., Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann. Neurol. 46:1999;774-777.
29. Svejgard A., Ryder L.P. HLA and disease - a survey. Immunol. Rev. 70:1982;193-218.
30. Svejgard A., Ryder L.P. HLA and disease associations: detecting the strongest association. Tissue Antigens. 43:1994;18-27.
31. Tommerup N., Leffers H. Assignment of the human genes encoding 14-3-3 eta (YWHAH) to 22q12, 14-3-3 zeta (YWHAZ) to 2p25.1-p25.2, and 14-3-3 beta (YWHAB) to 20q13.1 by in situ hybridisation. Genomics. 33:1996;149-150.
32. Vincenz C., Dixit V.M. 14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules. J. Biol. Chem. 271:1996;20029-20034.
33. Watanabe M., Isobe T., Okuyama T., Ichimura T., Kuwano R., Takahashi Y., Kondo H. Molecular cloning of cDNA to rat 14-3-3 eta chain polypeptide and the neuronal expression of the mRNA in the central nervous system. Mol. Brain Res. 10:1991;151-158.
34. Watanabe M., Isobe T., Ichimura T., Kuwano R., Takahashi Y., Kondo H., Inoue Y. Molecular cloning of rat cDNAs for the ζ and θ subtypes of 14-3-3 protein and differential distributions of their mRNAs in the brain. Mol. Brain Res. 25:1994;113-121.
35. Wilhelmsen K., Mirel D., Marder K., Bernstein M., Naini A., Leal S.M., Cote L.J., Tang M.-X., Freyer G., Graziano J., Mayeux R. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann. Neurol. 41:1997;813-817.
36. Wiltfang J., Otto M., Baxter H.C., Bodemer M., Steinacker P., Bahn E., Zerr I., Kornhuber J., Kretzschmar H.A., Poser S., Ruther E., Aitken A. Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J. Neurochem. 73:1999;2485-2490.
37. Wintermeyer P., Krüger R., Kuhn W., Müller T., Woitalla D., Berg D., Becker G., Leroy E., Polymeropoulos M., Berger K., Przuntek H., Schöls L., Epplen J.T., Riess O. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport. 11:2000;2079-2082.
38. Xing H., Zhang S., Weinheimer C., Kovacs A., Muslin A.J. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J. 19:2000;349-358.
39. Xu J., Kao S.-Y., Lee F.J.S., Song W., Jin L.-W., Yankner B.A. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8:2002;600-606.
40. Zerr I., Bodemer M., Gefeller O., Otto M., Poser S., Wiltfang J., Windl O., Kretzschmar H.A., Weber T. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 43:1998;32-40.
41. Zhang L., Chen J., Fu H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc. Natl. Acad. Sci. USA. 96:1999;8511-8515.